tiprankstipranks
Advertisement
Advertisement
Jasper Therapeutics Receives Nasdaq Minimum Bid Price Notice
PremiumCompany AnnouncementsJasper Therapeutics Receives Nasdaq Minimum Bid Price Notice
1M ago
Jasper Therapeutics Launches Strategic Alternatives Review Amid Uncertainty
Premium
Company Announcements
Jasper Therapeutics Launches Strategic Alternatives Review Amid Uncertainty
2M ago
Jasper Therapeutics initiates review of strategic alternatives
Premium
The Fly
Jasper Therapeutics initiates review of strategic alternatives
2M ago
Jasper Therapeutics price target lowered to $7 from $12 at Evercore ISI
PremiumThe FlyJasper Therapeutics price target lowered to $7 from $12 at Evercore ISI
4M ago
Jasper Therapeutics’ Deep Cuts May Backfire: Analyst Warns Downsizing Could Undermine Briquilimab Strategy and Cash Runway
Premium
Company Announcements
Jasper Therapeutics’ Deep Cuts May Backfire: Analyst Warns Downsizing Could Undermine Briquilimab Strategy and Cash Runway
4M ago
Buy Rating on Jasper: Briquilimab’s Strong CSU Efficacy, Favorable Safety, and Competitive Profile Underpin Key Near‑Term Value Driver
Premium
Ratings
Buy Rating on Jasper: Briquilimab’s Strong CSU Efficacy, Favorable Safety, and Competitive Profile Underpin Key Near‑Term Value Driver
4M ago
Briquilimab’s Robust Efficacy and Favorable Safety in Urticaria Indicate Strong Upside for Jasper Therapeutics and Support a Buy Rating
PremiumRatingsBriquilimab’s Robust Efficacy and Favorable Safety in Urticaria Indicate Strong Upside for Jasper Therapeutics and Support a Buy Rating
6M ago
Jasper Therapeutics Reports Strong Briquilimab Data in Urticaria
Premium
Company Announcements
Jasper Therapeutics Reports Strong Briquilimab Data in Urticaria
6M ago
Jasper Therapeutics reports updated data from briquilimab studies
Premium
The Fly
Jasper Therapeutics reports updated data from briquilimab studies
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100